Phenytoin

Product: Calcitonin (salmon)

Identifier : DBSNPE000023
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • C Allele (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : (C;C) / (A;C)
Type(s) : Effect Directly Studied
Groups : Non-functional CYP2C9; Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. Epub 2005 Apr 1. [PubMed:15805193 ]

PMID: 22827572

Phenytoin

Product: GJ103 (sodium salt)

Identifier : DBSNPE000140
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Multidrug resistance protein 1
Gene Name : ABCB1
UniProt ID : P08183
Defining Change(s) :

  • T Allele (C3435T) (rs1045642 )

Allele Name : MDR1*T
Genotype(s) : (T;T) / (C;T)
Type(s) : Effect Directly Studied
Groups : Not Available
Description : Increased phenytoin effects due to higher plasma phenytoin levels
References :

  1. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Guzelbey P, Roots I, Brinkmann U: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001;1(3):204-10. [PubMed:11908757 ]

PMID: 17145782

Phenytoin

Product: Monastrol

Identifier : DBSNPE000241
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : HLA class I histocompatibility antigen, B-15 alpha chain
Gene Name : HLA-B
UniProt ID : P30464
Defining Change(s) :

  • HLA-B*15:02

Allele Name : HLA-B*15:02
Genotype(s) : Not Available
Type(s) : ADR Directly Studied
Groups : Not Available
Description : Increased risk of Stevens–Johnson syndrome and toxicepidermal necrolysis
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]

PMID: 11011045

Phenytoin

Product: PJ34 (hydrochloride)

Identifier : DBSNPE004985
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 681G>A (rs4244285 )

Allele Name : CYP2C19*2A
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 9114068

Phenytoin

Product: Lomustine

Identifier : DBSNPE004986
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 681G>A (rs4244285 )

Allele Name : CYP2C19*2B
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 25313322

Phenytoin

Product: PI4KIII beta inhibitor 3

Identifier : DBSNPE004987
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 636G>A (rs4986893 )

Allele Name : CYP2C19*3
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 27235821

Phenytoin

Product: Bavisant (dihydrochloride hydrate)

Identifier : DBSNPE004988
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 1A>G (rs28399504 )

Allele Name : CYP2C19*4
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 24678947

Phenytoin

Product: Bavisant (dihydrochloride)

Identifier : DBSNPE004989
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 1297C>T (rs56337013 )

Allele Name : CYP2C19*5
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 26550826

Phenytoin

Product: Bavisant

Identifier : DBSNPE004990
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 395G>A (rs72552267 )

Allele Name : CYP2C19*6
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 21623631

Phenytoin

Product: Gambogic Acid

Identifier : DBSNPE004991
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 19294T>A (rs72558186 )

Allele Name : CYP2C19*7
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 16996040

Phenytoin

Product: Rufinamide

Identifier : DBSNPE004992
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 557G>C (rs140278421 )
  • 991A>G

Allele Name : CYP2C19*22
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 14657341

Phenytoin

Product: GZD824

Identifier : DBSNPE004993
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 99C>T (rs17885098 )
  • 991A>G (rs3758581 )
  • 1004G>A (rs118203757 )
  • 1197A>G

Allele Name : CYP2C19*24
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 22886506

Phenytoin

Product: Clevidipine

Identifier : DBSNPE004994
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 12662A>G (rs12769205 )

Allele Name : CYP2C19*35
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, risk of drug toxicity.
References :

  1. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 24277867

Phenytoin

Product: Forskolin

Identifier : DBSNPE004995
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 430C>T (rs1799853 )

Allele Name : CYP2C9*2
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 18825744

Phenytoin

Product: BAM7

Identifier : DBSNPE004996
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 8945621

Phenytoin

Product: AEE788

Identifier : DBSNPE004997
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1076T>C (rs56165452 )

Allele Name : CYP2C9*4
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 20048077

Phenytoin

Product: 20-HETE

Identifier : DBSNPE004998
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1080C>G (rs28371686 )

Allele Name : CYP2C9*5
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 16461588

Phenytoin

Product: Miriplatin (hydrate)

Identifier : DBSNPE004999
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 449G>A (rs7900194 )

Allele Name : CYP2C9*8
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 16782823

Phenytoin

Product: MK-3207

Identifier : DBSNPE005000
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1003C>T (rs28371685 )

Allele Name : CYP2C9*11
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 15534916

Phenytoin

Product: Lck Inhibitor

Identifier : DBSNPE005001
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1465C>T (rs9332239 )

Allele Name : CYP2C9*12
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 8576907

Phenytoin

Product: AZD3514

Identifier : DBSNPE005002
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 269T>C (rs72558187 )

Allele Name : CYP2C9*13
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 7768881

Phenytoin

Product: Pitolisant (oxalate)

Identifier : DBSNPE005003
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>A (rs72558189 )

Allele Name : CYP2C9*14
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 21686136

Phenytoin

Product: Balaglitazone

Identifier : DBSNPE005004
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 895A>G (rs72558192 )

Allele Name : CYP2C9*16
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 27708394

Phenytoin

Product: 360A

Identifier : DBSNPE005005
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C
  • 1190A>C
  • 1425A>T

Allele Name : CYP2C9*18
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 15312648

Phenytoin

Product: Pyridostatin

Identifier : DBSNPE005006
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 389C>G

Allele Name : CYP2C9*26
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 24172895

Phenytoin

Product: LY2801653 (dihydrochloride)

Identifier : DBSNPE005007
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 641A>T

Allele Name : CYP2C9*28
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 10970698

Phenytoin

Product: A 83-01

Identifier : DBSNPE005008
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1429G>A

Allele Name : CYP2C9*30
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 1379515

Phenytoin

Product: XMD17-109

Identifier : DBSNPE005009
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 395G>A (rs200183364 )

Allele Name : CYP2C9*33
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 1693879

Phenytoin

Product: Mifepristone

Identifier : DBSNPE005010
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 818delA (rs9332131 )

Allele Name : CYP2C9*6
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 11478874

Phenytoin

Product: Leuprolide (Acetate)

Identifier : DBSNPE005011
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 485C>A (rs72558190 )

Allele Name : CYP2C9*15
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 9924797

Phenytoin

Product: Bivalirudin (Trifluoroacetate)

Identifier : DBSNPE005012
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 353_362delAGAAATGGAA (rs72558188 )

Allele Name : CYP2C9*25
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 12883265

Phenytoin

Product: IPA-3

Identifier : DBSNPE005013
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>T
  • 430C>T

Allele Name : CYP2C9*35
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, risk of drug toxicity. Consider lower dose.
References :

  1. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6. [PubMed:25099164 ]
  2. Dilantin-125® (Phenytoin Oral Suspension, USP)[package insert]. New York City, New York: Parke-Davis, Division of Pfizer Inc; 2015. [Link]

PMID: 12030814

Phenytoin

Product: NVP-BEP800

Identifier : DBSNPE005830
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 818delA (rs9332131 )

Allele Name : CYP2C9*6
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 Dec;11(9):803-8. [PubMed:11740344 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 24316736

Phenytoin

Product: Elesclomol

Identifier : DBSNPE005831
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 485C>A (rs72558190 )

Allele Name : CYP2C9*15
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 21683433

Phenytoin

Product: BIIB021

Identifier : DBSNPE005832
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 353_362delAGAAATGGAA (rs72558188 )

Allele Name : CYP2C9*25
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 22274912

Phenytoin

Product: Tirofiban (hydrochloride monohydrate)

Identifier : DBSNPE005833
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>T
  • 430C>T

Allele Name : CYP2C9*35
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, Desideri A, Borgiani P: Characterization of a novel CYP2C9 gene mutation and sdivuctural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics. 2011 Jun;21(6):344-6. doi: 10.1097/FPC.0b013e328344c340. [PubMed:21451434 ]
  2. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M: High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenomics J. 2014 Aug;14(4):343-9. doi: 10.1038/tpj.2013.41. Epub 2013 Dec 10. [PubMed:24322786 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 24556694

Phenytoin

Product: Rivastigmine (tartrate)

Identifier : DBSNPE005834
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 430C>T (rs1799853 )

Allele Name : CYP2C9*2
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39-42. [PubMed:8004131 ]
  2. Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997 Jun;7(3):203-10. [PubMed:9241660 ]
  3. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30. [PubMed:15070684 ]
  4. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E: The impact of CYP2C9 genetics and oral condivaceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos. 2004 May;32(5):484-9. [PubMed:15100169 ]
  5. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  6. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 22791293

Phenytoin

Product: Rivastigmine

Identifier : DBSNPE005835
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996 Aug;6(4):341-9. [PubMed:8873220 ]
  2. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, sdivuctural characterization, subsdivate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996 Sep 15;333(2):447-58. [PubMed:8809086 ]
  3. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 Feb 27;353(9154):717-9. [PubMed:10073515 ]
  4. Kidd RS, Sdivaughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80. [PubMed:10208645 ]
  5. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven subsdivates. Pharmacogenetics. 2000 Mar;10(2):95-104. [PubMed:10761997 ]
  6. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K: Genetic polymorphisms and functional characterization of the 5-flanking region of the human CYP2C9 gene: in vidivo and in vivo studies. Clin Pharmacol Ther. 2001 Aug;70(2):175-82. [PubMed:11503012 ]
  7. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  8. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 20396627

Phenytoin

Product: MK-0592

Identifier : DBSNPE005836
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1076T>C (rs56165452 )

Allele Name : CYP2C9*4
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB: Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84. [PubMed:20150829 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19339240

Phenytoin

Product: Atazanavir

Identifier : DBSNPE005837
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1080C>G (rs28371686 )

Allele Name : CYP2C9*5
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 Aug;60(2):382-7. [PubMed:11455026 ]
  2. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004 Aug;76(2):113-8. [PubMed:15289788 ]
  3. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 17909057

Phenytoin

Product: Octreotide (acetate)

Identifier : DBSNPE005838
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 449G>A (rs7900194 )

Allele Name : CYP2C9*8
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH: Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther. 2012 Apr;91(4):660-5. doi: 10.1038/clpt.2011.269. Epub 2012 Feb 29. [PubMed:22378156 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 20075161

Phenytoin

Product: Temozolomide

Identifier : DBSNPE005839
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1003C>T (rs28371685 )

Allele Name : CYP2C9*11
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Higashi MK, Veensdiva DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [PubMed:11926893 ]
  2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  3. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  4. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  5. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 22004374

Phenytoin

Product: PF-04447944

Identifier : DBSNPE005840
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1465C>T (rs9332239 )

Allele Name : CYP2C9*12
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 18971326

Phenytoin

Product: Skepinone-L

Identifier : DBSNPE005841
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 269T>C (rs72558187 )

Allele Name : CYP2C9*13
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004 Jul;14(7):465-9. [PubMed:15226678 ]
  2. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005 Jun;33(6):749-53. Epub 2005 Mar 11. [PubMed:15764711 ]
  3. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 2005 Sep;35(9):853-61. [PubMed:16308280 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 21093591

Phenytoin

Product: Empagliflozin

Identifier : DBSNPE005842
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>A (rs72558189 )

Allele Name : CYP2C9*14
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 16672921

Phenytoin

Product: Bitopertin

Identifier : DBSNPE005843
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 895A>G (rs72558192 )

Allele Name : CYP2C9*16
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 15190076

Phenytoin

Product: BMS-626530

Identifier : DBSNPE005844
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C
  • 1190A>C
  • 1425A>T

Allele Name : CYP2C9*18
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 17891158

Phenytoin

Product: BMN-674

Identifier : DBSNPE005845
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 389C>G

Allele Name : CYP2C9*26
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11884448

Phenytoin

Product: MK592

Identifier : DBSNPE005846
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 641A>T

Allele Name : CYP2C9*28
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11916905

Phenytoin

Product: AM680

Identifier : DBSNPE005847
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1429G>A

Allele Name : CYP2C9*30
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11354382

Phenytoin

Product: SB-674043

Identifier : DBSNPE005848
Drug : DB00252 (Phenytoin)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 395G>A (rs200183364 )

Allele Name : CYP2C9*33
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements
References :

  1. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Horio T, Takiuchi S, Kawano Y, Minematsu K, Naritomi H, Tomoike H, Sawada J, Miyata T: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res. 2008 Aug;31(8):1549-57. doi: 10.1291/hypres.31.1549. [PubMed:18971529 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 24651609

By

Related Post